Information Provided By:
Fly News Breaks for August 2, 2017
RMD
Aug 2, 2017 | 06:30 EDT
BofA/Merrill analyst William Dunlop downgraded ResMed to Neutral with a reduced price target of A$9.90. The analyst says the company's FY18 gross margin range of around 58.2% lessen his enthusiasm for its CPAP business prospects.
News For RMD From the Last 2 Days
There are no results for your query RMD